STOCK TITAN

BIO-TECHNE TO PRESENT AT THE BARCLAYS 26th ANNUAL GLOBAL HEALTHCARE CONFERENCE

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Bio-Techne Corporation (TECH) President and CEO to present at Barclays Global Healthcare Conference. Live webcast available on Bio-Techne's Investor Relations website.
Positive
  • None.
Negative
  • None.

MINNEAPOLIS, March 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024, at 8:30 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

About Bio-Techne Corporation (NASDAQ:TECH)

Contact:

David Clair, Vice President, Investor Relations & Corporate Development


david.clair@bio-techne.com


612-656-4416  

Bio-Techne

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-barclays-26th-annual-global-healthcare-conference-302080964.html

SOURCE Bio-Techne Corporation

Kim Kelderman will present on Wednesday, March 13, 2024, at 8:30 a.m. EDT.

The live webcast can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Bio-Techne Corp

NASDAQ:TECH

TECH Rankings

TECH Latest News

TECH Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
US
Minneapolis

About TECH

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.